LEXX Valuation

Lexaria Bioscience Corp

Add to Watchlist

Advanced Chart

0.889

-0.006(-0.670%)1D

Overview
Forecast
Valuation
Earnings

LEXX Relative Valuation

LEXX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LEXX is overvalued; if below, it's undervalued.

Historical Valuation

Lexaria Bioscience Corp (LEXX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 66.65 is considered Overvalued compared with the five-year average of -3.15. The fair price of Lexaria Bioscience Corp (LEXX) is between 0.22 to 0.80 according to relative valuation methord. Compared to the current price of 0.89 USD , Lexaria Bioscience Corp is Overvalued By 11.44%.

Relative Value

Fair Zone

0.22-0.80

Current Price：0.89

11.44%

Overvalued

-1.53

Trailing

Forward

0.00

EV/EBITDA

Lexaria Bioscience Corp. (LEXX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.56. The thresholds are as follows: Strongly Undervalued below -9.75, Undervalued between -9.75 and -5.16, Fairly Valued between 4.04 and -5.16, Overvalued between 4.04 and 8.64, and Strongly Overvalued above 8.64. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.15

EV/EBIT

Lexaria Bioscience Corp. (LEXX) has a current EV/EBIT of -1.15. The 5-year average EV/EBIT is -1.82. The thresholds are as follows: Strongly Undervalued below -6.82, Undervalued between -6.82 and -4.32, Fairly Valued between 0.67 and -4.32, Overvalued between 0.67 and 3.17, and Strongly Overvalued above 3.17. The current Forward EV/EBIT of -1.15 falls within the Historic Trend Line -Fairly Valued range.

66.65

Lexaria Bioscience Corp. (LEXX) has a current PS of 66.65. The 5-year average PS is 42.50. The thresholds are as follows: Strongly Undervalued below -11.69, Undervalued between -11.69 and 15.41, Fairly Valued between 69.60 and 15.41, Overvalued between 69.60 and 96.70, and Strongly Overvalued above 96.70. The current Forward PS of 66.65 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Lexaria Bioscience Corp. (LEXX) has a current P/OCF of 0.00. The 5-year average P/OCF is -3.21. The thresholds are as follows: Strongly Undervalued below -11.53, Undervalued between -11.53 and -7.37, Fairly Valued between 0.95 and -7.37, Overvalued between 0.95 and 5.11, and Strongly Overvalued above 5.11. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Lexaria Bioscience Corp. (LEXX) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.44. The thresholds are as follows: Strongly Undervalued below -14.16, Undervalued between -14.16 and -8.30, Fairly Valued between 3.42 and -8.30, Overvalued between 3.42 and 9.28, and Strongly Overvalued above 9.28. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Lexaria Bioscience Corp (LEXX) has a current Price-to-Book (P/B) ratio of 3.15. Compared to its 3-year average P/B ratio of 3.39 , the current P/B ratio is approximately -6.92% higher. Relative to its 5-year average P/B ratio of 3.81, the current P/B ratio is about -17.29% higher. Lexaria Bioscience Corp (LEXX) has a Forward Free Cash Flow (FCF) yield of approximately -51.06%. Compared to its 3-year average FCF yield of -34.49%, the current FCF yield is approximately 48.03% lower. Relative to its 5-year average FCF yield of -26.91% , the current FCF yield is about 89.76% lower.

3.15

P/B

Median3y

3.39

Median5y

3.81

-51.06

FCF Yield

Median3y

-34.49

Median5y

-26.91

Competitors Valuation Multiple

The average P/S ratio for LEXX's competitors is 17.96, providing a benchmark for relative valuation. Lexaria Bioscience Corp Corp (LEXX) exhibits a P/S ratio of 66.65, which is 271.08% above the industry average. Given its robust revenue growth of 107.14%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LEXX.O

Lexaria Bioscience Corp

Performance Decomposition

Market capitalization of LEXX decreased by 78.26% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 84.00K to 174.00K.

The secondary factor is the Margin Expansion, contributed 2.56%to the performance.

Overall, the performance of LEXX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

107.14%

84.00K → 174.00K

Revenue Growth

2.56%

-2.12K → -2.18K

Margin Expansion

-187.96%

1.52 → -1.34

P/E Change

-78.26%